Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $8.0 million.

  • Harmony Biosciences Holdings' Gains from Investment Securities rose 771.1% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 771.1%. This contributed to the annual value of $7.2 million for FY2024, which is 1331.15% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Gains from Investment Securities stood at $8.0 million, which was up 771.1% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Gains from Investment Securities registered a high of $21.1 million during Q4 2024, and its lowest value of $467000.0 during Q1 2024.
  • Over the past 5 years, Harmony Biosciences Holdings' median Gains from Investment Securities value was $6.6 million (recorded in 2022), while the average stood at $7.1 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 9231.61% in 2024, then surged by 160869.79% in 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Gains from Investment Securities (Quarter) stood at $2.0 million in 2021, then surged by 50.23% to $2.9 million in 2022, then skyrocketed by 297.21% to $11.7 million in 2023, then skyrocketed by 80.38% to $21.1 million in 2024, then tumbled by 62.13% to $8.0 million in 2025.
  • Its Gains from Investment Securities was $8.0 million in Q3 2025, compared to $8.0 million in Q2 2025 and $8.0 million in Q1 2025.